Drug Insights

Accessing Mupirocin Information on Synapse: A Step-by-Step Approach

29 February 2024
2 min read

Mupirocin, also known by its brand name CENTANY®, is a small molecule drug that works as an RNA synthetase inhibitor to treat bacterial infections. It is commonly used to treat impetigo and other skin infections caused by Gram-positive bacteria. Originally developed by GSK, Mupirocin was first approved for use in 1987. CENTANY® ointment is a topical medication used to treat impetigo by inhibiting bacterial growth and stopping the spread of infection. Click on the image below to begin the exploration journey of Mupirocin through the Synapse database!

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

METTL1 tRNA Methyltransferase Inhibitors by STORM Therapeutics at ESMO
Latest Hotspot
3 min read
METTL1 tRNA Methyltransferase Inhibitors by STORM Therapeutics at ESMO
29 February 2024
STORM Therapeutics will showcase research on its innovative METTL1 tRNA Methyltransferase blockers at the ESMO event for specialized cancer treatments.
Read →
An analysis of Enzalutamide's R&D progress and its clinical results presented at the 2024 ASCO_GU Annual Meeting
An analysis of Enzalutamide's R&D progress and its clinical results presented at the 2024 ASCO_GU Annual Meeting
29 February 2024
On Jan 25, 2024, the 2024 ASCO_GU reported results from suspending enzalutamide combo tx in high-risk BCR prostate cancer men.
Read →
FDA Fast-Tracks Linvoseltamab Review for Relapsed/Refractory Multiple Myeloma
Latest Hotspot
3 min read
FDA Fast-Tracks Linvoseltamab Review for Relapsed/Refractory Multiple Myeloma
29 February 2024
FDA hastens assessment of a new application for Linvoseltamab, aimed at treating recurring or resistant forms of Multiple Myeloma.
Read →
Maximize Your Synapse Use: Your Guide to Searching Oxybutynin
Drug Insights
2 min read
Maximize Your Synapse Use: Your Guide to Searching Oxybutynin
29 February 2024
Oxybutynin, marketed as DITROPAN®, is a medication approved by the US FDA in 1975 for the treatment of overactive bladder.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.